Literature DB >> 7956604

Inhibition of gastrointestinal motility by MPTP via adrenergic and dopaminergic mechanisms.

Y Haskel1, M Hanani.   

Abstract

The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was injected intraperitoneally in mice and caused an acute inhibition (of over 60%) of gastrointestinal motility, which was measured by the transit of charcoal. This inhibition was not related to conversion of MPTP to MPP+. Administration of the beta-adrenergic blocker propranolol significantly reduced, but did not completely block, the effect of MPTP. The dopaminergic blocker haloperidol also partly reversed the effects of MPTP. When these blockers were administered together, the action of MPTP was fully blocked. The results indicate that the toxin acted by releasing catecholamines (presumably norepinephrine and dopamine), thereby inhibiting motility.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7956604     DOI: 10.1007/BF02087652

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  12 in total

1.  Depletion of norepinephrine in mouse heart by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mimicked by 1-methyl-4-phenylpyridinium (MPP+) and not blocked by deprenyl.

Authors:  R W Fuller; S K Hemrick-Luecke
Journal:  Life Sci       Date:  1986-11-03       Impact factor: 5.037

2.  Effect of duodenal ulcerogens cysteamine, mepirizole, and MPTP on duodenal myoelectric activity in rats.

Authors:  J C Mangla; G Pihan; H A Brown; S Rattan; S Szabo
Journal:  Dig Dis Sci       Date:  1989-04       Impact factor: 3.199

3.  MPTP-induced duodenal ulcers in rat. Prevention by reuptake blockers for serotonin and norepinephrine, but not dopamine.

Authors:  A Keshavarzian; A Wibowo; J H Gordon; J Z Fields
Journal:  Gastroenterology       Date:  1990-03       Impact factor: 22.682

4.  Duodenal ulcer induced by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).

Authors:  S Szabo; A Brown; G Pihan; H Dali; J L Neumeyer
Journal:  Proc Soc Exp Biol Med       Date:  1985-12

5.  The effect of nalbuphine on gastrointestinal transit in mice.

Authors:  C L Wong
Journal:  Eur J Pharmacol       Date:  1987-03-17       Impact factor: 4.432

6.  Chronic alterations in jejunal myoelectric activity in rats due to MPTP.

Authors:  E Y Eaker; G B Bixler; A J Dunn; W V Moreshead; J R Mathias
Journal:  Am J Physiol       Date:  1987-12

7.  Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine (MPTP) on ganglionic transmission.

Authors:  K A Alkadhi; Y H Hogan
Journal:  J Auton Pharmacol       Date:  1992-02

Review 8.  MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease.

Authors:  M Gerlach; P Riederer; H Przuntek; M B Youdim
Journal:  Eur J Pharmacol       Date:  1991-12-12       Impact factor: 4.432

Review 9.  MPTP toxicity: implications for research in Parkinson's disease.

Authors:  I J Kopin; S P Markey
Journal:  Annu Rev Neurosci       Date:  1988       Impact factor: 12.449

10.  Rapid effects of MPTP in the mouse colon.

Authors:  M Hanani
Journal:  Eur J Pharmacol       Date:  1990-01-17       Impact factor: 4.432

View more
  11 in total

1.  Decreased dopamine receptor expression and its second-messenger cAMP in malignant human colon tissue.

Authors:  S Basu; P S Dasgupta
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

2.  Dopamine, by acting through its D2 receptor, inhibits insulin-like growth factor-I (IGF-I)-induced gastric cancer cell proliferation via up-regulation of Krüppel-like factor 4 through down-regulation of IGF-IR and AKT phosphorylation.

Authors:  Subhalakshmi Ganguly; Biswarup Basu; Saurav Shome; Tushar Jadhav; Sudipta Roy; Jahar Majumdar; Partha Sarathi Dasgupta; Sujit Basu
Journal:  Am J Pathol       Date:  2010-11-12       Impact factor: 4.307

3.  D1 and D2 dopamine receptor-mediated inhibition of activated normal T cell proliferation is lost in jurkat T leukemic cells.

Authors:  Biswarup Basu; Chandrani Sarkar; Debanjan Chakroborty; Subhalakshmi Ganguly; Saurav Shome; Partha Sarathi Dasgupta; Sujit Basu
Journal:  J Biol Chem       Date:  2010-06-30       Impact factor: 5.157

4.  Gastrointestinal dysfunction in a Parkinson's disease rat model and the changes of dopaminergic, nitric oxidergic, and cholinergic neurotransmitters in myenteric plexus.

Authors:  Hong Can Zhu; Jing Zhao; Chang Yue Luo; Qian Qian Li
Journal:  J Mol Neurosci       Date:  2011-06-07       Impact factor: 3.444

Review 5.  Glucuronides in the gut: Sugar-driven symbioses between microbe and host.

Authors:  Samuel J Pellock; Matthew R Redinbo
Journal:  J Biol Chem       Date:  2017-04-07       Impact factor: 5.157

6.  Downregulation of sulfotransferase expression and activity in diseased human livers.

Authors:  Emine B Yalcin; Vijay More; Karissa L Neira; Zhenqiang James Lu; Nathan J Cherrington; Angela L Slitt; Roberta S King
Journal:  Drug Metab Dispos       Date:  2013-06-17       Impact factor: 3.922

Review 7.  Bladder and bowel dysfunction in Parkinson's disease.

Authors:  R Sakakibara; T Uchiyama; T Yamanishi; K Shirai; T Hattori
Journal:  J Neural Transm (Vienna)       Date:  2008-03-10       Impact factor: 3.575

8.  Bladder, bowel, and sexual dysfunction in Parkinson's disease.

Authors:  Ryuji Sakakibara; Masahiko Kishi; Emina Ogawa; Fuyuki Tateno; Tomoyuki Uchiyama; Tatsuya Yamamoto; Tomonori Yamanishi
Journal:  Parkinsons Dis       Date:  2011-09-12

9.  Clinical Phenotypes of Parkinson's Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes.

Authors:  Sarah Vascellari; Marta Melis; Vanessa Palmas; Silvia Pisanu; Alessandra Serra; Daniela Perra; Maria Laura Santoru; Valentina Oppo; Roberto Cusano; Paolo Uva; Luigi Atzori; Micaela Morelli; Giovanni Cossu; Aldo Manzin
Journal:  Biomolecules       Date:  2021-01-22

10.  Chemotaxis of Escherichia coli to major hormones and polyamines present in human gut.

Authors:  Joana G Lopes; Victor Sourjik
Journal:  ISME J       Date:  2018-07-11       Impact factor: 10.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.